FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979463318> ?p ?o ?g. }

• W2979463318 endingPage "888" @default.
• W2979463318 startingPage "888" @default.
• W2979463318 abstract "Abstract Abstract 888 Novel therapies are needed for patients with relapsed or refractory hairy cell leukemia (HCL), particularly those who have failed purine analogs. CD22 is expressed in the majority of B-cell malignancies and universally in HCL, making it an ideal therapeutic target. CAT-8015 is a targeted immunotoxin composed of an anti-CD22 antibody fused to a modified form of Pseudomonas exotoxin A. It has a novel mechanism of action compared with other CD22 targeted antibodies, as CAT-8015 is internalized upon binding to CD22, inhibiting protein translation and prompting apoptosis. CAT-8015 has shown significant antitumor activity in B-cell tumor cell lines and malignant cells isolated from patients with HCL. CAT-8015 (HA22) is a high-affinity derivative of CAT-3888 (BL22) that displays higher CD22-binding and inhibitory activity due to mutation of 3 amino acids. A multicenter, dose-escalation, phase I study is being conducted to estimate the maximum tolerated dose (MTD) of CAT-8015, and evaluate its safety, efficacy and immunogenicity profiles in HCL. Adult HCL patients who previously received at least 2 systemic therapies (including purine analogs) and had cytopenias or symptomatic splenomegaly requiring treatment are eligible to participate. A standard 3+3 dose-escalation design is being employed at doses of 5, 10, 20, 30, 40, and 50 ug/kg. CAT-8015 is administered as a 30-min IV infusion on days 1, 3, and 5 (QODx3) of each 28-day cycle for up to a total of 10 cycles until disease progression, intervening toxicity [e.g. dose-limiting toxicity (DLT)], completion of two cycles of treatment beyond documentation of complete response (CR), or other reason for which the patient might become ineligible. Patients receive premedication with hydroxyzine, ranitidine, and acetaminophen to prevent infusion reactions; and low-dose aspirin and IV hydration to prevent hemolytic uremic syndrome (HUS), which has been observed in association with CAT-3888. Data are electronically archived by each investigator and were pooled for analysis. The study is ongoing with 2 more patients expected to be treated at 50 ug/kg. A total of 26 patients have received CAT-8015 to date. Three patients enrolled at each of the 5, 10, 20, and 30 ug/kg dose levels; 4 patients at the 40 ug/kg dose level; and 10 patients at 50 ug/kg dose level. The median age is 59 years (range 40-77), and the majority (84.6%) are male. Patients were heavily pretreated (median number of prior therapies: 3, range 2-7). Among the 26 patients in total, 14 received prior rituximab (53.8%); among 10 patients in cohort 50 ug/kg, 7 received prior rituximab (70.0%). Patients have received a median of 3 treatment cycles (range 1-8). No DLTs have been observed and an MTD has not been reached. Expanded enrollment at 50 ug/kg has been undertaken to better characterize the safety profile and antitumor activity. The most common drug-related toxicities have been of grade 2 or lower severity: hypoalbuminemia (57.7%), peripheral edema (42.3%), pyrexia (38.5%), elevated ALT (34.6%) and AST (30.8%), headaches (26.9%), and nausea (26.9%). Four patients (15.4%) developed grade 2 vascular leak syndrome (VLS). One treatment-related serious adverse event occurred, a reversible grade 2 HUS that was reported in the 30 ug/kg dose cohort. Anti-drug antibodies developed in 10 patients (38.5%). CAT-8015 was highly active in HCL. Among the 26 patients treated, the objective response (OR) rate was 73.1% (19/26), with a CR rate of 34.6% (9 patients) and a partial response (PR) rate of 38.5% (10 patients). Responses were observed at all dose levels. Specific OR rates at the 5,10, 20, 30, 40, and 50 ug/kg/dose cohorts were 100%, 100%, 33%, 33%, 75% and 80%, respectively. At the time of this report, none of the patients achieving a CR has relapsed. Four of 9 (44.4%) patients with CR have a duration of response of >12 months. CAT-8015 exhibited an acceptable safety profile when administered up to 50 ug/kg QOD × 3, and demonstrated substantial antitumor activity in patients with relapsed/refractory HCL. These data demonstrate that CAT-8015 is a promising new product candidate for patients with advanced HCL. These data support further investigation in newly diagnosed patients with HCL and suggest that CAT-8015 may have clinical activity in other B-cell malignancies Disclosures: Kreitman: NIH: Patents & Royalties. Off Label Use: Recombinant immunotoxin HA22 for targeting CD22+ cells. Robak:MedImmune, LLC: Research Funding. FitzGerald:NIH: Patents & Royalties. Pastan:NIH: Patents & Royalties." @default.
• W2979463318 created "2019-10-18" @default.
• W2979463318 creator A5001124933 @default.
• W2979463318 creator A5015491065 @default.
• W2979463318 creator A5025737516 @default.
• W2979463318 creator A5025784315 @default.
• W2979463318 creator A5038268549 @default.
• W2979463318 creator A5041784203 @default.
• W2979463318 creator A5049385918 @default.
• W2979463318 creator A5056573254 @default.
• W2979463318 creator A5065696086 @default.
• W2979463318 creator A5077359225 @default.
• W2979463318 creator A5082882030 @default.
• W2979463318 creator A5087571749 @default.
• W2979463318 date "2009-11-20" @default.
• W2979463318 modified "2023-10-06" @default.
• W2979463318 title "Phase I Dose-Escalation Study of CAT-8015 (HA22), A CD22-Specific Targeted Immunotoxin, in Relapsed or Refractory Hairy Cell Leukemia." @default.
• W2979463318 doi "https://doi.org/10.1182/blood.v114.22.888.888" @default.
• W2979463318 hasPublicationYear "2009" @default.
• W2979463318 type Work @default.
• W2979463318 sameAs 2979463318 @default.
• W2979463318 citedByCount "6" @default.
• W2979463318 countsByYear W29794633182012 @default.
• W2979463318 countsByYear W29794633182015 @default.
• W2979463318 crossrefType "journal-article" @default.
• W2979463318 hasAuthorship W2979463318A5001124933 @default.
• W2979463318 hasAuthorship W2979463318A5015491065 @default.
• W2979463318 hasAuthorship W2979463318A5025737516 @default.
• W2979463318 hasAuthorship W2979463318A5025784315 @default.
• W2979463318 hasAuthorship W2979463318A5038268549 @default.
• W2979463318 hasAuthorship W2979463318A5041784203 @default.
• W2979463318 hasAuthorship W2979463318A5049385918 @default.
• W2979463318 hasAuthorship W2979463318A5056573254 @default.
• W2979463318 hasAuthorship W2979463318A5065696086 @default.
• W2979463318 hasAuthorship W2979463318A5077359225 @default.
• W2979463318 hasAuthorship W2979463318A5082882030 @default.
• W2979463318 hasAuthorship W2979463318A5087571749 @default.
• W2979463318 hasConcept C109246011 @default.
• W2979463318 hasConcept C109316439 @default.
• W2979463318 hasConcept C111700020 @default.
• W2979463318 hasConcept C115085202 @default.
• W2979463318 hasConcept C126322002 @default.
• W2979463318 hasConcept C142424586 @default.
• W2979463318 hasConcept C159654299 @default.
• W2979463318 hasConcept C181199279 @default.
• W2979463318 hasConcept C182179738 @default.
• W2979463318 hasConcept C185592680 @default.
• W2979463318 hasConcept C202751555 @default.
• W2979463318 hasConcept C203014093 @default.
• W2979463318 hasConcept C2776476023 @default.
• W2979463318 hasConcept C2778453870 @default.
• W2979463318 hasConcept C2778461978 @default.
• W2979463318 hasConcept C2780483514 @default.
• W2979463318 hasConcept C2780868878 @default.
• W2979463318 hasConcept C542903549 @default.
• W2979463318 hasConcept C55493867 @default.
• W2979463318 hasConcept C71924100 @default.
• W2979463318 hasConcept C86803240 @default.
• W2979463318 hasConcept C87355193 @default.
• W2979463318 hasConcept C98274493 @default.
• W2979463318 hasConceptScore W2979463318C109246011 @default.
• W2979463318 hasConceptScore W2979463318C109316439 @default.
• W2979463318 hasConceptScore W2979463318C111700020 @default.
• W2979463318 hasConceptScore W2979463318C115085202 @default.
• W2979463318 hasConceptScore W2979463318C126322002 @default.
• W2979463318 hasConceptScore W2979463318C142424586 @default.
• W2979463318 hasConceptScore W2979463318C159654299 @default.
• W2979463318 hasConceptScore W2979463318C181199279 @default.
• W2979463318 hasConceptScore W2979463318C182179738 @default.
• W2979463318 hasConceptScore W2979463318C185592680 @default.
• W2979463318 hasConceptScore W2979463318C202751555 @default.
• W2979463318 hasConceptScore W2979463318C203014093 @default.
• W2979463318 hasConceptScore W2979463318C2776476023 @default.
• W2979463318 hasConceptScore W2979463318C2778453870 @default.
• W2979463318 hasConceptScore W2979463318C2778461978 @default.
• W2979463318 hasConceptScore W2979463318C2780483514 @default.
• W2979463318 hasConceptScore W2979463318C2780868878 @default.
• W2979463318 hasConceptScore W2979463318C542903549 @default.
• W2979463318 hasConceptScore W2979463318C55493867 @default.
• W2979463318 hasConceptScore W2979463318C71924100 @default.
• W2979463318 hasConceptScore W2979463318C86803240 @default.
• W2979463318 hasConceptScore W2979463318C87355193 @default.
• W2979463318 hasConceptScore W2979463318C98274493 @default.
• W2979463318 hasIssue "22" @default.
• W2979463318 hasLocation W29794633181 @default.
• W2979463318 hasOpenAccess W2979463318 @default.
• W2979463318 hasPrimaryLocation W29794633181 @default.
• W2979463318 hasRelatedWork W1542801784 @default.
• W2979463318 hasRelatedWork W1996144185 @default.
• W2979463318 hasRelatedWork W2001626604 @default.
• W2979463318 hasRelatedWork W2062085883 @default.
• W2979463318 hasRelatedWork W2063108415 @default.
• W2979463318 hasRelatedWork W2090926667 @default.
• W2979463318 hasRelatedWork W2335889607 @default.
• W2979463318 hasRelatedWork W2979463318 @default.
• W2979463318 hasRelatedWork W2979734784 @default.
• W2979463318 hasRelatedWork W4242672750 @default.
• W2979463318 hasVolume "114" @default.

• next